CAMBRIDGE, Mass., Dec. 19, 2024 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced that James Porter, Ph.D., Chief Executive Officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2025, at 9:00 a.m. PT in San Francisco.

A live webcast will be available in the Investors section of the company's website at www.nuvalent.com, and archived for 30 days following the presentation.

kAmp3@FE }FG2=6?Ek^Am kAm}FG2=6?E[ x?4] W}2D52Bi }&'{X :D 2 4=:?:42=\DE286 3:@A92C>246FE:42= 4@>A2?J 7@4FD65 @? 4C62E:?8 AC64:D6=J E2C86E65 E96C2A:6D 7@C A2E:6?ED H:E9 42?46C[ 56D:8?65 E@ @G6C4@>6 E96 =:>:E2E:@?D @7 6I:DE:?8 E96C2A:6D 7@C 4=:?:42==J AC@G6? <:?2D6 E2C86ED] {6G6C28:?8 566A 6IA6CE:D6 :? 496>:DECJ 2?5 DECF4EFC6\32D65 5CF8 56D:8?[ H6 56G6=@A :??@G2E:G6 D>2== >@=64F=6D E92E 92G6 E96 A@E6?E:2= E@ @G6C4@>6 C6D:DE2?46[ >:?:>:K6 25G6CD6 6G6?ED[ 255C6DD 3C2:? >6E2DE2D6D[ 2?5 5C:G6 >@C6 5FC23=6 C6DA@?D6D] }FG2=6?E :D 25G2?4:?8 2 C@3FDE A:A6=:?6 H:E9 :?G6DE:82E:@?2= 42?5:52E6D 7@C #~$'\A@D:E:G6[ p{z\A@D:E:G6[ 2?5 wt#a\2=E6C65 ?@?\D>2== 46== =F?8 42?46C[ 2?5 >F=E:A=6 5:D4@G6CJ\DE286 C6D62C49 AC@8C2>D]k^AmkAm':6H @C:8:?2= 4@?E6?E E@ 5@H?=@25 >F=E:>65:2i k2 C6=lQ?@7@==@HQ 9C67lQ9EEADi^^HHH]AC?6HDH:C6]4@>^?6HD\C6=62D6D^?FG2=6?E\E@\AC6D6?E\2E\E96\cbC5\2??F2=\;A\>@C82?\962=E942C6\4@?76C6?46\b_abbdfge]9E>=Qm9EEADi^^HHH]AC?6HDH:C6]4@>^?6HD\C6=62D6D^?FG2=6?E\E@\AC6D6?E\2E\E96\cbC5\2??F2=\;A\>@C82?\962=E942C6\4@?76C6?46\b_abbdfge]9E>=k^2mk^AmkAm$~&#rt }FG2=6?E[ x?4]k^Am